• 温医大首页
  • 加入收藏
  • 联系我们
  • 院长信箱

培养工作

正文

当前位置:

首页 旧版 培养工作 通知公告 正文

关于2016级硕士《检验医学进展》课程上课的通知(4月14日)

发表时间:2017-04-07 10:07:10 点击量:次 分享到

硕士研究生《检验医学进展》课程将于下周继续上课,具体安排如下:

                   
 

时间

 
 

讲座题目

 
 

主讲人

 
 

地点

 
 

上课对象

 
 

414日(周五)下午1330

 
 

Anti-metastatic effect of the TM4SF5-specific peptide  vaccine and humanized monoclonal antibody on colon cancer in a mouse lung  metastasis model

 
 

吴广

 
 

同心楼六楼会议室

 
 

2016级硕士研究生

 

吴广

 Dr.Wu is an Assistant Research Fellow at the Medical Science ResearchCenter of Hallym University, Korea. He received his Ph.D. degree from the Collegeof Medicine, Hallym University in 2011. From 2012-2015, he underwentpostdoctoral fellowship training at Medical Science Research Center of HallymUniversity. His research focuses on the production of monoclonal antibodies againsttumor-associated antigens and their functions.

讲座简介

  Transmembrane 4 superfamily member 5 protein (TM4SF5) isa potential therapeutic target for hepatocellular carcinoma (HCC) and coloncancer. We designed a cyclic peptide targeting TM4SF5. Cyclic peptide-specificantibodies were produced in mice after immunization with a complex of thepeptide, CpG-DNA, and liposomes. Intravenous injection of the CT-26 mouse coloncancer cell line into mice induced tumors in the lung. Immunization with thepeptide vaccine improved the survival rate and reduced the growth of lungtumors. We established a monoclonal antibody specific to the cyclicTM4SF5-based peptide and humanized the antibody sequence by complementaritydetermining region-grafting. The humanized antibody was reactive to the cyclicpeptide and TM4SF5 protein. Treatment of CT-26 cells with the humanizedantibody reduced cell motility in vitro. Furthermore, direct injection of thehumanized anti-TM4SF5 antibody in vivo reduced growth of lung tumors in mousemetastasis model. Therefore, we conclude that the immunization with the cyclicpeptide vaccine and injection of the TM4SF5-specifc humanized antibody have ananti-metastatic effect against colon cancer in mice. Importantly, the humanizedantibody may serve as a starting platform for further development andapplication in clinical settings.